Jefferson's Kimmel Cancer Center and the department of radiology at Thomas Jefferson University in Philadelphia received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a method that may stage prostate cancers and detect recurrent disease, potentially reducing the number of confirmation biopsies. The technique involves the use of a PET scan and a novel imaging agent.
In the wake of a study published April 17 in the Journal of the American Medical Association ( JAMA) which reported an increased incidence of gastrointestinal morbidity among men with prostate cancer treated with proton therapy compared with intensity-modulated radiation therapy (IMRT), proton therapy providers have rallied to dispute the findings and study methodology.
Nelly Tan, MD, and Sean P. Zivin, MD, have been selected by the American Roentgen Ray Society (ARRS) as the recipients of resident travel grants, sponsored by Fujifilm Medical Systems.
Treatment of localized prostate cancer with intensity-modulated radiation therapy (IMRT) may provide improved disease control with less morbidity than conformal radiation therapy, according to an analysis published April 17 in the Journal of the American Medical Association. However, proton therapy did not appear to provide additional benefits for these patients.
The radiopharmaceutical, I-131-MIP-1466, which is designed to deliver a therapeutic dose of radiation to metastatic prostate cancer, will enter a clinical trial to evaluate its efficacy and benefits for patients.
The team at Johns Hopkins In-Vivo Cellular and Molecular Imaging Center in Baltimore is using novel imaging tools to discover new early detection methods for cancers existing in cells, and study its prevention and elimination before spreading to other organs and tissues.
The results of three studies, released Oct. 21 during a meeting of the North Central Section of the American Urological Association, validated previous research that suggested C-11 choline PET/CT scans can be utilized as a staging and potentially therapeutic tool in prostate cancer.
89Zr-desferrioxamine B-7E11 displays high tumor-to-background tissue contrast in immuno-PET and can be used as a tool to monitor and quantify with high specificity tumor response in prostate-specific membrane antigen (PSMA)-positive prostate cancer, according to research published in the October issue of the Journal of Nuclear Medicine.
MD Anderson Cancer Center in Houston has initiated orders of Cesium-131 brachytherapy seeds from IsoRay, as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer, which is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatment.
Over the next decade, the population of cancer survivors over 65 years of age will increase by approximately 42 percent, according to a report published in the October issue of Cancer Epidemiology, Biomarkers & Prevention.
Researchers at UCLA’s Jonsson Comprehensive Cancer Center have developed a gene-based imaging system to target castration resistant prostate cancers (CRPCs), potentially allowing oncologists to find and treat metastases faster.
The synthetic amino acid analog radiotracer anti-1-amino-3- 18F-fluorocyclobutane-1-carboxylic acid ( anti-3- 18F-FACBC) with PET/CT is more sensitive than 111In-capromab pendetide in the detection of recurrent prostate carcinoma.
A steady reduction in overall cancer death rates translates into the avoidance of about 898,000 deaths from cancer between 1990 and 2007, according to the latest statistics from the American Cancer Society (ACS).
|
|
|
|
RSS 
